Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
Matthew J. Matasar(Rutgers, The State University of New Jersey), Jennifer L. Crombie(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Srikanth Ambati(Regeneron (United States)), Julia Zecchini(Regeneron (United States)), John N. Allan(Cornell University), Jeffrey A. Barnes(Harvard University), Hesham Mohamed(Bristol-Myers Squibb (United States)), Jingxian Cai(Regeneron (United States)), Stephen M. Ansell(Mayo Clinic), Uri Abadi(Tel Aviv University), Neta Goldschmidt(National Institutes of Health), Jean‐Marie Michot(Institut Gustave Roussy), Max S. Topp(Universitätsklinikum Würzburg), Min Zhu(Eye & ENT Hospital of Fudan University), Irit Avivi Mazza, Jurriaan Brouwer‐Visser(Montefiore Medical Center), Aafia Chaudhry(Regeneron (United States)), Susan O’Brien(University of California, Irvine)
Cited by 2
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k